A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

NCT01484275 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

High-risk Smoldering Multiple Myeloma

Interventions

DRUG: Siltuximab
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC